A new treatment approach significantly improves survival rates for patients with inherited BRCA1 and BRCA2 breast cancer genes, following a successful trial. Professor Jean Abraham led the Partner trial which demonstrated two innovations: the addition of a targeted cancer drug, olaparib, and chemotherapy pre-surgery, and the benefits of careful timing of when the treatments are given to patients. Jackie took part in the trial when diagnosed in February 2019 with a small but aggressive tumour. “S

If you have a history of breast cancer and a mutation in an inherited breast cancer gene (i.e., BRCA1/2, PALB2, ATM, or CHEK2), you may be eligible to contribute to tumor genomics studies that are being conducted through the Inherited Cancer Registry (ICARE). Through this effort, we are researching: - breast cancer characteristics - factors associated with outcomes, including treatments - studying genomics of the tumors to better understand pathways to tumor development, which can hopefully lead